{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:37:40Z","timestamp":1778215060830,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,22]],"date-time":"2014-09-22T00:00:00Z","timestamp":1411344000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2369-15-154","type":"journal-article","created":{"date-parts":[[2014,9,22]],"date-time":"2014-09-22T15:01:23Z","timestamp":1411398083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study"],"prefix":"10.1186","volume":"15","author":[{"given":"Janet K","family":"Freburger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit V","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Alan","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,22]]},"reference":[{"issue":"1","key":"845_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0272-6386(99)70103-4","volume":"34","author":"A Besarab","year":"1999","unstructured":"Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999, 34 (1): 21-28. 10.1016\/S0272-6386(99)70103-4.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"845_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/ajkd.2001.21293","volume":"37","author":"C Charytan","year":"2001","unstructured":"Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis. 2001, 37 (2): 300-307. 10.1053\/ajkd.2001.21293.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"845_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1681\/ASN.2006091034","volume":"18","author":"DW Coyne","year":"2007","unstructured":"Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007, 18 (3): 975-984. 10.1681\/ASN.2006091034.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"845_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.amjmed.2012.11.030","volume":"126","author":"AV Kshirsagar","year":"2013","unstructured":"Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term effectiveness of iron dosing and formulations in U.S. hemodialysis patients. Am J Med. 2013, 126 (6): 541-e541-541.e514","journal-title":"Am J Med"},{"issue":"20","key":"845_CR5","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Drueke","year":"2006","unstructured":"Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006, 355 (20): 2071-2084. 10.1056\/NEJMoa062276.","journal-title":"N Engl J Med"},{"issue":"21","key":"845_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, Mcgill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009, 361 (21): 2019-2032. 10.1056\/NEJMoa0907845.","journal-title":"N Engl J Med"},{"issue":"20","key":"845_CR7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006, 355 (20): 2085-2098. 10.1056\/NEJMoa065485.","journal-title":"N Engl J Med"},{"issue":"4","key":"845_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1525-139X.2006.00174.x","volume":"19","author":"UC Brewster","year":"2006","unstructured":"Brewster UC: Intravenous iron therapy in end-stage renal disease. Semin Dial. 2006, 19 (4): 285-290. 10.1111\/j.1525-139X.2006.00174.x.","journal-title":"Semin Dial"},{"issue":"11","key":"845_CR9","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/ndt\/15.11.1827","volume":"15","author":"J Parkkinen","year":"2000","unstructured":"Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000, 15 (11): 1827-1834. 10.1093\/ndt\/15.11.1827.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"845_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1525-139X.2004.17115.x","volume":"17","author":"UC Brewster","year":"2004","unstructured":"Brewster UC, Perazella MA: Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial. 2004, 17 (1): 57-60.","journal-title":"Semin Dial"},{"issue":"3","key":"845_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.femsim.2004.11.010","volume":"43","author":"JJ Bullen","year":"2005","unstructured":"Bullen JJ, Rogers HJ, Spalding PB, Ward CG: Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol. 2005, 43 (3): 325-330. 10.1016\/j.femsim.2004.11.010.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"845_CR12","doi-asserted-by":"crossref","first-page":"250A","DOI":"10.1681\/ASN.V9112108","volume":"9","author":"AJ Collins","year":"1998","unstructured":"Collins AJ, Ebben J, Ma JZ, Xia H: Iron dosing patterns and mortality [abstract]. J Am Soc Nephrol. 1998, 9: 250A-","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"845_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2190001","volume":"219","author":"B Halliwell","year":"1984","unstructured":"Halliwell B, Gutteridge JM: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 1984, 219 (1): 1-14.","journal-title":"Biochem J"},{"issue":"6","key":"845_CR14","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1093\/ndt\/gfr711","volume":"27","author":"A Martin-Malo","year":"2012","unstructured":"Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, Crespo R, Ramirez R, Aljama P: Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant. 2012, 27 (6): 2465-2471. 10.1093\/ndt\/gfr711.","journal-title":"Nephrol Dial Transplant"},{"key":"845_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.nu.05.070185.002053","volume":"5","author":"A Sevanian","year":"1985","unstructured":"Sevanian A, Hochstein P: Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr. 1985, 5: 365-390. 10.1146\/annurev.nu.05.070185.002053.","journal-title":"Annu Rev Nutr"},{"issue":"5","key":"845_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0891-5849(95)02173-6","volume":"20","author":"JA Berliner","year":"1996","unstructured":"Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996, 20 (5): 707-727. 10.1016\/0891-5849(95)02173-6.","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"845_CR17","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","volume":"62","author":"J Himmelfarb","year":"2002","unstructured":"Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62 (5): 1524-1538. 10.1046\/j.1523-1755.2002.00600.x.","journal-title":"Kidney Int"},{"issue":"7","key":"845_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1681\/ASN.2012121164","volume":"24","author":"MA Brookhart","year":"2013","unstructured":"Brookhart MA, Freburger JK, Ellis K, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Nephrol Soc. 2013, 24 (7): 1151-1158. 10.1681\/ASN.2012121164.","journal-title":"J Am Nephrol Soc"},{"issue":"11","key":"845_CR19","doi-asserted-by":"publisher","first-page":"e78930","DOI":"10.1371\/journal.pone.0078930","volume":"8","author":"AV Kshirsagar","year":"2013","unstructured":"Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term cardiovascular safety of intravenous iron dosing in hemodialysis patients. PLOS One. 2013, 8 (11): e78930-10.1371\/journal.pone.0078930.","journal-title":"PLOS One"},{"key":"845_CR20","volume-title":"Researcher's Guide to the USRDS Database,2011","author":"U.S. Renal Data System Coordinating Center","year":"2012","unstructured":"U.S. Renal Data System Coordinating Center: Researcher's Guide to the USRDS Database,2011. 2012, Bethesda, MD: National Institutes of Health, NIDDK"},{"issue":"1","key":"845_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care. 1998, 36 (1): 8-27. 10.1097\/00005650-199801000-00004.","journal-title":"Med Care"},{"key":"845_CR22","doi-asserted-by":"publisher","first-page":"796270","DOI":"10.1155\/2013\/796270","volume":"2013","author":"X Xie","year":"2013","unstructured":"Xie X, Strickler HD, Xue X: Additive hazard regression models: an application to the natural history of human papillomavirus. Comput Math Methods Med. 2013, 2013: 796270-","journal-title":"Comput Math Methods Med"},{"key":"845_CR23","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","volume":"84","author":"DY Lin","year":"1989","unstructured":"Lin DY, Wei LJ: The robust inference for the proportional hazards model. J Am Stat Assoc. 1989, 84: 1074-1078. 10.1080\/01621459.1989.10478874.","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"845_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology. 2000, 11 (5): 550-560. 10.1097\/00001648-200009000-00011.","journal-title":"Epidemiology"},{"issue":"5","key":"845_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"MA Hernan","year":"2000","unstructured":"Hernan MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000, 11 (5): 561-570. 10.1097\/00001648-200009000-00012.","journal-title":"Epidemiology"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-15-154\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T20:41:50Z","timestamp":1717360910000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-15-154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-15-154","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,22]]},"assertion":[{"value":"8 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"154"}}